170 related articles for article (PubMed ID: 31103918)
1. Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design.
Machiraju PK; Yedla P; Gubbala SP; Bohari T; Abdul JKV; Xu S; Patel R; Chittireddy VRR; Boppana K; Jagarlapudi SARP; Neamati N; Syed R; Amanchy R
Comput Biol Chem; 2019 Jun; 80():374-383. PubMed ID: 31103918
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties.
Lee JW; Park J; Kim J; Kim J; Choi C; Min KH
Eur J Med Chem; 2021 Apr; 216():113298. PubMed ID: 33689933
[TBL] [Abstract][Full Text] [Related]
3. Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors.
Kim C; Kim E
Curr Med Chem; 2019; 26(42):7623-7640. PubMed ID: 29932031
[TBL] [Abstract][Full Text] [Related]
4. Role of CSF1R 550th-tryptophan in kusunokinin and CSF1R inhibitor binding and ligand-induced structural effect.
Chompunud Na Ayudhya C; Graidist P; Tipmanee V
Sci Rep; 2024 May; 14(1):12531. PubMed ID: 38822100
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors.
Ramachandran SA; Jadhavar PS; Miglani SK; Singh MP; Kalane DP; Agarwal AK; Sathe BD; Mukherjee K; Gupta A; Haldar S; Raja M; Singh S; Pham SM; Chakravarty S; Quinn K; Belmar S; Alfaro IE; Higgs C; Bernales S; Herrera FJ; Rai R
Bioorg Med Chem Lett; 2017 May; 27(10):2153-2160. PubMed ID: 28377059
[TBL] [Abstract][Full Text] [Related]
6. Reprofiling of pyrimidine-based DAPK1/CSF1R dual inhibitors: identification of 2,5-diamino-4-pyrimidinol derivatives as novel potential anticancer lead compounds.
Farag AK; Hassan AHE; Ahn BS; Park KD; Roh EJ
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):311-324. PubMed ID: 31809612
[TBL] [Abstract][Full Text] [Related]
7. De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments.
Urich R; Wishart G; Kiczun M; Richters A; Tidten-Luksch N; Rauh D; Sherborne B; Wyatt PG; Brenk R
ACS Chem Biol; 2013 May; 8(5):1044-52. PubMed ID: 23534475
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Structure-Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5- d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors.
Xun Q; Zhang Z; Luo J; Tong L; Huang M; Wang Z; Zou J; Liu Y; Xu Y; Xie H; Tu ZC; Lu X; Ding K
J Med Chem; 2018 Mar; 61(6):2353-2371. PubMed ID: 29499108
[TBL] [Abstract][Full Text] [Related]
9. First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent.
Farag AK; Hassan AHE; Jeong H; Kwon Y; Choi JG; Oh MS; Park KD; Kim YK; Roh EJ
Eur J Med Chem; 2019 Jan; 162():161-175. PubMed ID: 30445265
[TBL] [Abstract][Full Text] [Related]
10. Csf1r or Mer inhibition delays liver regeneration via suppression of Kupffer cells.
Santamaria-Barria JA; Zeng S; Greer JB; Beckman MJ; Seifert AM; Cohen NA; Zhang JQ; Crawley MH; Green BL; Loo JK; Maltbaek JH; DeMatteo RP
PLoS One; 2019; 14(5):e0216275. PubMed ID: 31042769
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CSF1R and AKT by (±)-kusunokinin hinders breast cancer cell proliferation.
Rattanaburee T; Tipmanee V; Tedasen A; Thongpanchang T; Graidist P
Biomed Pharmacother; 2020 Sep; 129():110361. PubMed ID: 32535390
[TBL] [Abstract][Full Text] [Related]
12. The c.1085A>G Genetic Variant of
Yeh YM; Hsu SJ; Lin PC; Hsu KF; Wu PY; Su WC; Chang JY; Shen MR
Clin Cancer Res; 2017 Oct; 23(20):6021-6030. PubMed ID: 28724665
[No Abstract] [Full Text] [Related]
13. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors.
Liang X; Wang C; Wang B; Liu J; Qi S; Wang A; Liu Q; Deng M; Wang L; Liu J; Liu Q
Eur J Med Chem; 2022 Dec; 243():114782. PubMed ID: 36179404
[TBL] [Abstract][Full Text] [Related]
15. 7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors.
Irie T; Sawa M
Chem Pharm Bull (Tokyo); 2018; 66(1):29-36. PubMed ID: 29311509
[TBL] [Abstract][Full Text] [Related]
16. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
Wen J; Wang S; Guo R; Liu D
Eur J Med Chem; 2023 Jan; 245(Pt 1):114884. PubMed ID: 36335744
[TBL] [Abstract][Full Text] [Related]
17. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.
Olmos-Alonso A; Schetters ST; Sri S; Askew K; Mancuso R; Vargas-Caballero M; Holscher C; Perry VH; Gomez-Nicola D
Brain; 2016 Mar; 139(Pt 3):891-907. PubMed ID: 26747862
[TBL] [Abstract][Full Text] [Related]
19. Selection of fragments for kinase inhibitor design: decoration is key.
Czodrowski P; Hölzemann G; Barnickel G; Greiner H; Musil D
J Med Chem; 2015 Jan; 58(1):457-65. PubMed ID: 25437144
[TBL] [Abstract][Full Text] [Related]
20. The azaindole framework in the design of kinase inhibitors.
Mérour JY; Buron F; Plé K; Bonnet P; Routier S
Molecules; 2014 Nov; 19(12):19935-79. PubMed ID: 25460315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
